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The response of breast cancer cells to growth factors requires a
complex interaction between growth factors and growth factor
receptors, followed by the activation of well-defined signal trans-
duction pathways that mediate a proliferative response. Not only
must signal transduction pathways be activated, but cellular
checkpoints must also be inactivated for a cell to proliferate. Thus,
the proliferative response includes the activation of early-response
genes as well as the inactivation of cell cycle repressor genes
(Muller et al, 1984), and may require the coordinated activation
and suppression of protein synthesis (Makino et al, 1984;
Greenberg et al, 1986).
There has been considerable interest in developing diagnostic,
prognostic and therapeutic modalities based on this information.
Although much attention has focused on growth factor/receptor
interactions, such as the immediate downstream effector elements
seen in receptor-activated tyrosine kinases, less attention has been
given to signalling events further downstream. In this regard,
calmodulin (CaM), a ubiquitous mediator of calcium-dependent
signal transduction, represents a compelling area for investigation
into the proliferative responses of malignant cells (Hait and Lazo,
1986; Lu and Means, 1993). For example, Chafouleas et al (1981)
reported that CaM was required for re-entry of quiescent Chinese
hamster ovary (CHO) cells into the cell cycle. Rasmussen and
Means (1987) demonstrated that overexpression of CaM increased
cell proliferation by decreasing the G1/S transit time, and that CaM
antisense blocked this effect (Rasmussen and Means, 1989).
Although CaM is a constitutively expressed protein in non-
dividing cells (Veigl et al, 1984), cellular transformation to malig-
nancy has been associated with increases in intracellular CaM
(Chafouleas et al, 1981). In addition, a positive correlation
between CaM levels and the growth rate of malignant cells has
been demonstrated (MacManus et al, 1981).
Despite these observations, the mechanism(s) by which CaM
exerts its effects on the growth of malignant cells remains unclear.
CaM-dependent protein kinases are central to many of the func-
tions mediated by CaM. Calmodulin-dependent protein kinase III
(CaM kinase III, elongation factor-2 kinase) is a unique member
of the CaM-dependent protein kinase family with one known
substrate, elongation factor 2 (eEF-2). The recently reported
purification, sequencing and cloning of CaM kinase III (Hait et al,
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enzyme lacks homology to other threonine/serine or tyrosine
kinases. The recognition that one other enzyme, myosin heavy-
chain kinase A, shares sequence homology with CaM kinase III in
the catalytic domain (Futey et al, 1995; Ryazanov et al, 1997)
suggests that CaM kinase III represents a new superfamily of
protein kinases (Ryazanov et al, 1997).
The activity of CaM kinase III is selectively activated in prolif-
erating cells (Bagaglio and Hait, 1994; Cheng et al, 1995; Hait et
al, 1996; Parmer et al, 1997). Rottlerin, a drug that inhibits CaM
kinase III activity, blocks cells at the G0/G1-S boundary and
induces cell death (Parmer et al, 1997).
Despite the emerging information on CaM kinase III in the
control of cell proliferation and viability, nothing is known about
the regulation of the enzyme in human breast cancer. Therefore,
we studied the activity of CaM kinase III and its regulation by
mitogens and expression during the cell cycle in several breast
cancer models.
MATERIALS AND METHODS
Breast tumour specimens and cell lines
MCF-7 (an oestrogen-dependent human breast carcinoma cell
line), MDA-MB-231 (an oestrogen-independent human breast
carcinoma cell line), HL-60 (human promyelocytic leukaemia
cells), T98G (human glioblastoma cells), C6 (N-nitrosomethyl-
urea-induced rat glioma line), OVCAR-3 (human ovarian adeno-
carcinoma cells) and KB (human oral epidermoid carcinoma) cells
were all obtained from the American Type Culture Collection.
MCF-7 cells were grown in Iscove’s modified Eagle medium
(IMEM) and MDA-MB-231 cells in Leibovitz (L-15) media. HL-
60 were grown in RPMI-1640, T98G were grown in Ham’s F-10
Dulbecco’s modified Eagle medium (DMEM) (1:10), and C6, KB
and OVCAR-3 cells were grown in DMEM. All media were
obtained from Gibco-BRL, Grand Island, NY, USA. All cell
lines were supplemented with 10% fetal bovine serum (FBS),
100 U ml–1 penicillin and 100 mg ml–1 streptomycin. All cell lines
had doubling times of approximately 24 h. Cultures were main-
tained at 37°C in a humidified atmosphere containing 5% carbon
dioxide/95% air. In experiments designed to elucidate the role of
CaM kinase III in the mitogenic response, cells in logarithmic
phase of growth were seeded at a density of 1 ´ 105 cells ml–1 and
were grown in a serum-free chemically defined medium (MCDB
105). All cells were routinely checked and found to be free of
mycoplasma and fungi.
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Figure 1 CaM kinase III activity in malignant cell lines and in human breast
carcinoma. CaM kinase III activity was determined by measuring the
phosphorylation of eEF-2. Cell lysates from HL-60 leukaemia cells, C6 (N-
nitrosomethylurea-induced rat glioma line), T98G (human glioblastoma cells),
OVCAR-3 (human ovarian adenocarcinoma cells), KB (human oral
epidermoid carcinoma), MDA-MB-231 (oestrogen receptor-negative breast
cancer), MCF-7 (an oestrogen-dependent human breast carcinoma cell line)
and human breast carcinoma (CA 1 and CA 2) were phosphorylated in assay
mixtures as described in Materials and methods. Equal amounts of protein
were incubated in the presence of 1.5 mM calcium chloride and 2 mM CaM.
Purified eEF-2 was added as exogenous substrate. After SDS-PAGE by
autoradiography, the phosphorylated eEF-2 band was quantified with
an Ambis radioanalytical imaging system. Each bar represents the
mean ± s.e.m. of at least three experiments
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Figure 2 Increased activity of CaM kinase III in human breast cancer specimens. (A) Unselected human breast cancer (T) and adjacent normal breast tissue
(N) specimens were obtained at the time of surgery by the Tissue Retrieval Service of The Cancer Institute of New Jersey. Tissues were prepared and assayed
for CaM kinase III activity as described in Materials and methods. Numbers at the bottom of each set refer to specimen identification in the Tissue Retrieval
Service databank. Evaluation of ‘normal’ breast tissue from specimens 323 and 389 found evidence of tumour cells (see Results and discussion). (B)
Unselected human breast cancers (T) and normal mammary tissue taken from patients undergoing breast reduction surgery (N) were homogenized and
analysed as described in Figure 1Sixteen fresh human breast cancer specimens (14 with matched
adjacent normal tissue) were obtained at the time of initial exci-
sional biopsy or at the time of definitive surgery. In addition,
normal mammary tissue was obtained during two breast reduction
mammoplasty operations. All specimens were procured through
the Tissue Retrieval Service of The Cancer Institute of New Jersey,
were frozen in liquid nitrogen within 1 h of excision and stored at
– 80°C until processed. No patients had received preoperative
hormonal treatment or chemotherapy.
Activity of CaM kinase III
Cell monolayers were removed using 0.05% trypsin, 0.5 mM
EDTA (Gibco-BRL) and washed in phosphate-buffered saline
(PBS). Fresh-frozen breast samples and cells were homogenized in
ice-cold buffer containing 25 mM Hepes pH 7.4, 100 mM sodium
chloride, 20 mM sodium pyrophosphate, 2 mM EDTA, 0.5 mM
phenylmethylsulphonyl fluoride (PMSF), 1.25 mg ml–1 leupeptin,
1.25 mg ml–1 pepstatin A and 2.5 mg ml–1 soybean trypsin inhibitor
using a Polytron homogenizer. The homogenate was then
centrifuged at 15 000 g for 30 min at 4°C. The protein concentra-
tion of the supernatants was determined according to the method
of Bradford using a Bio-Rad protein assay kit (Bio-Rad
Laboratories, Richmond, CA, USA) with bovine serum albumin
(BSA) as the standard. The phosphorylation of eEF-2 was
measured in 40-ml reaction mixtures containing 50 mM Hepes
pH 7.6, 10 mM magnesium chloride, 10 mg of protein, 1.5 mM
calcium chloride, 0.5 mg eEF-2 and 2 mM CaM (Calbiochem, San
Diego, CA, USA). After the addition of 20 mM [g-32P]ATP (3 mCi
per assay; Amersham, UK), reactions were carried out at 30°C for
2 min. Reactions were linear with respect to time of incubation and
amount of tissue. Phosphorylation was terminated by the addition
of 20 ml of 3 ´ Laemmli sample buffer containing 190 mM Tris
(pH 6.8), 6% sodium dodecyl sulphate (SDS), 30% glycerol, 15%
2-mercaptoethanol and 0.003% bromophenol blue dye. Samples
were boiled for 5 min and proteins were separated by SDS-PAGE
according to the method of Laemmli using an 8% resolving gel
and 4% stacking gel. Gels were fixed and stained in 40%
methanol/10% acetic acid/0.1% Coomassie brilliant blue R-250
(Bio-Rad), destained and dried.
For the analysis of radiolabelled proteins, Kodak X-Omat
XRP-5 film was exposed to dried gels at – 70°C for 24–48 h.
Phosphoimagery was performed using an Ambis radioanalytical
imagery system (Ambis, San Diego, CA, USA) and specific
activity was calculated from background-corrected data.
Sorting of MCF-7 cells
Approximately 5 ´ 104 MCF-7 cells were stained with Hoechst
33342 (10 mg ml–1) in growth medium for 30 min before
harvesting. The cells were removed from the flasks by trypsiniza-
tion, centrifuged (1000 g) for 5 min at 4°C, and the pellet was
washed and resuspended in PBS containing Hoechst dye. Before
analysis, the stained cells were passed through a 26-gauge needle
to ensure a single-cell suspension. Cells were analysed and sorted
using an Epics Elite flow cytometer (Coulter Electronics, Hialeah,
FL, USA) equipped with a Coherent 90, 5 W, adjustable wave-
length laser. Linear peak and integrated blue fluorescence signals
were collected using a 380-nm laser block, 588-nm dichroic long
and 418-nm longpass filters. A blue (peak signal) parameter
histogram was used to exclude cell debris, doublets and clumps
from the sorted populations. In a typical experiment, with sort
speeds of 2000 total events s–1, purity of the sorted populations was
greater than 98%. The histograms were analysed using Epics
Cyto-Logic Software.
Analysis of responses to growth factors
Growth factor studies were carried out using cells in logarithmic
phase plated initially in serum-supplemented media as described
above. After a 4–6 h attachment period, cells were washed three
times with serum-free MCDB 105 medium and cultured for 24 h
without mitogens to obtain baseline measurements.
Cells were then exposed, for 24 h, to either 10% FBS, insulin-like
growth factor I (IGF-I) (20 ng ml–1) and/or epidermal growth factor
(EGF) (10 ng ml–1) and/or rottlerin (5 mM), an inhibitor of CaM
kinase III activity (Carl Roth, Karlsruhe, Germany). Control cells
were maintained in MCDB 105 without growth factors or serum.
Cell proliferation was measured by BrdU incorporation. Briefly,
MDA-MB-231 cells were incubated with 10 mM BrdU for 45 min
at 37°C and harvested by trypsinization. Cells were then washed
with ice-cold PBS, resuspended in 200 ml PBS and fixed by drop-
wise addition of cold 70% ethanol while vortexing. The cells were
resuspended and incubated for 30 min in 2 N hydrochloric
acid/0.5% Triton X-100 in PBS and neutralized by rinsing once in
0.1 M sodium tetraborate (pH 8.5). Fluorescein isothiocyanate
(FITC)-conjugated anti-BrdU antibodies (Becton Dickinson) were
added (10 mg per sample) in 50 ml of 0.5% Tween 20/1% BSA in
PBS and incubated for 30 min. The cells were washed and resus-
pended in 1 ml of PBS containing 5 mg ml–1 propidium iodide.
Fluorescence intensities were determined by quantitative flow
cytometry and profiles were generated on a Becton Dickinson
FACScan analyser.
Statistical analysis
Statistical analysis of results from the cell line experiments was
carried out using ANOVA with a Student–Newman–Keuls
method of multiple comparisons (Snedecor and Cochran, 1980).
Comparisons of breast cancer surgical specimens and adjacent
normal tissue were performed with the Wilcoxon rank-sum test.
RESULTS AND DISCUSSION
CaM kinase III is a unique mitogen-activated protein kinase,
confirmed by purification (Hait et al, 1996) and cloning of the full-
length cDNAs from rat (Redpath et al, 1996; Ryazanov et al,
1997), Caenorhabditis elegans, mouse and human (Ryazanov et
al, 1997). We found that the sequence of the kinase was distinct
from all known protein kinases with the exception of myosin
heavy-chain kinase A and, therefore, appears to represent a new
superfamily of protein kinases (Ryazanov et al, 1997).
The current data demonstrate that the activity of CaM kinase III
is markedly increased in human breast cancer, and that the activity
of this enzyme is controlled by growth factor stimulation. As
shown in Figure 1, the activity of CaM kinase III in human breast
cancer cell lines was equal to or greater than that seen in a variety
of cell lines with similar rates of proliferation. In fact, MCF-7 cells
had the greatest specific activity of the enzyme found in an
analysis of seven cell lines and several human breast tumours.
The activity of the kinase is also markedly increased in breast
cancer specimens compared with that of adjacent normal breast
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‘lumpectomies’ and four mastectomies. In adjacent ‘normal’
tissue, we found either no detectable activity (specimens 159, 160,
351, 354, 532, 1123, 1171, 1222, 1246, 1336 and 1389) or far less
activity (specimens 313, 323 and 389). Pathological evaluation of
adjacent ‘normal’ breast tissue from two of these specimens (323
and 389) found evidence of tumour cells. Because no activity was
detected in ‘normal’ breast tissue samples taken from patients
undergoing reduction mammoplasty (Figure 2B), it is possible that
the activity detected in the ‘normal’ breast tissue adjacent to the
tumour in specimen 313 represents unrecognized contamination of
this tissue with cancer cells, or activation of the enzyme in response
to the tumour. It is also possible that increased CaM kinase III
activity is a characteristic of malignant precursors. In fact, we have
detected low CaM kinase III activity in specimens from patients
with pure ductal carcinoma in situ (DCIS) (TJ Kearney, TG Palmer,
VH Vyas and WN Hait unpublished data). Histological examina-
tion determined that the cellularity of the tumour specimens was
greater than that of the adjacent normal tissue. Therefore, we reas-
sayed five representative specimens normalizing for cell number.
The activity of CaM kinase III, whether normalized for protein or
cell number, was markedly increased in breast tumour specimens
compared with that of normal adjacent breast tissue.
An alternative explanation for the apparent increase in CaM
kinase III activity in breast carcinoma was the presence of endoge-
nous inhibitors of eEF-2 phosphorylation in normal mammary
tissue. This was excluded by mixing equivalent amounts of
homogenates from normal mammary tissue and breast tumours, in
which we found no inhibition of eEF-2 phosphorylation (data not
shown). We also determined whether the absence of eEF-2 phos-
phorylation in normal mammary tissue was due to the presence of
increased phosphatase activity. Purified eEF-2 was phosphoryl-
ated by purified CaM kinase III in the presence of [g-32P]ATP
followed by the addition of 10 mM ATP. This [32P]eEF-2 was then
incubated with homogenates of normal mammary gland for 0–
20 min. No degradation of added [32P]eEF-2 was observed during
this incubation period (data not shown).
These data may have implications for the diagnosis of breast
cancer. CaM kinase III activity was virtually absent in normal
breast tissue. When detected in normal tissue adjacent to the breast
cancer, the normal tissue was found to contain infiltrating tumour
cells. Therefore, detection of CaM kinase III activity may be an
early marker of invasive breast cancer.
The activity of CaM kinase III is stimulated by peptide growth
factors. As shown in Figure 3A, serum deprivation significantly
62 TG Parmer et al
British Journal of Cancer (1999) 79(1), 59–64 © Cancer Research Campaign 1999
10% FBS
SF
IGF-I
EGF
IGF-I + EGF
Rottlerin
0
20
30
40
50
C
a
M
 
k
i
n
a
s
e
 
I
I
I
 
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
)
10
IGF-I + EGF
+Rottlerin
b
b
a
b b
a
b
10% FBS
SF
IGF-I
EGF
IGF-I + EGF
Rottlerin
IGF-I + EGF
+Rottlerin
40
30
20
10
0
B
r
d
U
 
(
%
 
i
n
c
o
r
p
o
r
a
t
i
o
n
)
b
b b
a
b
b
a
B
A
Figure 3 Effect of growth factors and rottlerin on CaM kinase III activity and
cell proliferation in MDA-MB-231 breast cancer cells. Cells in logarithmic
phase were plated initially in serum-supplemented media as described in
Materials and methods. After a 4–6-h attachment period, cells were washed
with serum-free media (MCDB 105) and cultured for 24 h without mitogens.
Cells were then exposed to either EGF (10 ng ml–1) and/or IGF-I (20 ng ml–1),
rottlerin (5 mM), or 10% FBS for 24 h. Control cells were maintained in
serum-free media without growth factors. (A) CaM kinase III activity was
measured in cell lysates as described in Figure 1. Each bar represents the
mean ± s.e.m. from three separate experiments (P ≤ 0.05, a vs b). (B) Cell
proliferation was measured by BrdU incorporation as described in Materials
and methods. Fluorescence intensities were determined by quantitative flow
cytometry and profiles were generated on a Becton Dickinson FACScan
analyser. Each bar represents the mean ± s.e.m. from three separate
experiments (P ≤ 0.10, a vs b)
Figure 4 CaM kinase III activity during the cell cycle. MCF-7 cells were
plated at 1 ´ 105 cells ml–1. At 48 h after plating, cells were trypsinized and
separated by fluorescence-activated cell sorting as described in Materials
and methods. Equal amounts of protein or equal cell numbers from each
fraction were assayed for CaM kinase III activity as described in Figure 1.
Each bar represents the mean ± s.e.m. for each phase of the cell cycle from
three separate experiments
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G0/G1 G2/M Sdecreased (P ≤ 0.05) CaM kinase III activity and cell proliferation
in MDA-MB-231 cells to 13% of that seen when cells were main-
tained in 10% FBS. Treatment of serum-deprived MDA-MB-231
cells with either IGF-I or EGF alone stimulated CaM kinase III
activity to ≤ 35% of that of 10% serum (Figure 3B). In contrast, the
combination of these two growth factors activated CaM kinase III
levels to that observed in the presence of 10% serum (P ≤ 0.05)
(Figure 3A). Whereas the individual growth factors failed to stim-
ulate cell proliferation, the combination of IGF-I and EGF signifi-
cantly increased proliferation to levels similar to that observed in
cells maintained in 10% serum (P ≤ 0.10) (Figure 3B). The activity
of CaM kinase III and cell proliferation induced by EGF and IGF-
I was blocked by rottlerin, a CaM kinase III inhibitor (Figure 3).
MDA-MB-231, an oestrogen-independent breast cancer cell line,
was used to isolate the effects of peptide growth factors from that
of steroid hormones on CaM kinase III activity. We are currently
conducting experiments using MCF-7 cells to determine whether
oestrogen can regulate the activity of this enzyme. Preliminary
data (TJ Kearney et al, unpublished data) suggest that oestradiol
also stimulates CaM kinase III activity in breast cancer cells.
We and others obtained similar results for CaM kinase III in
other tissues. For example, Bagaglio et al (1994) found that serum
deprivation markedly diminished the expression of CaM kinase III
activity in rat glioma cells, whereas addition of serum promoted
the onset of proliferation and the activation of the kinase. Other
growth factors that activate CaM kinase III have been reported to
stimulate the growth of fibroblasts such as EGF, vasopressin,
bradykinin (Palfrey et al, 1987) and insulin (Levenson and
Blackshear, 1989).
Previous studies have shown that rottlerin, a 5,7-dihydroxy-2,2-
dimethyl-6-(2,4,6-trihydroxy-3-methyl-5-acetylbenzyl)-8-cinna-
moyl-1,2-chromene isolated from the pericarps of Mallotus
phillipinensis (Gschwendt et al, 1994), was an effective inhibitor of
CaM kinase III activity in glioma cells (Parmer et al, 1997).
Rottlerin blocks growth factor induced activation of CaM kinase III
and blocks cell proliferation in breast cancer cells (Figure 3).
Rottlerin has also been reported to inhibit the activity of PKC-d.
However, it was shown that it was the activation of PKC-d that led
to growth inhibition in NIH 3T3 cells (Mischak et al, 1993) and cell
cycle arrest in CHO cells (Watanabe et al, 1992). The signal trans-
duction cascade and proliferative response initiated by IGF-I and
EGF in breast cancer activates CaM kinase III and inhibition of this
enzyme, by rottlerin, blocks growth factor-induced proliferation.
Therefore, the identification of more potent and selective CaM
kinase III inhibitors may help identify new breast cancer therapies.
The response to growth factors requires a complex interaction
between growth factors and growth factor receptors, followed
by the activation of well-defined signal transduction pathways
that mediate a proliferative response. This area of biology has
contributed to our modern understanding of cellular proliferation
and to the development of new targets for anti-cancer therapies. In
breast cancer, this understanding led to the development of anti-
oestrogens such as tamoxifen. Although much recent attention has
focused on growth factor/receptor interactions, such as the imme-
diate downstream effector elements seen on receptor-activated
tyrosine kinases, less attention has been given to signalling events
further downstream. In this regard, CaM-dependent pathways
represent a compelling area for investigation into the proliferative
responses of malignant cells. Numerous studies have suggested the
importance of CaM-mediated signalling in cell proliferation and
malignant transformation (Chafouleas et al, 1981; MacManus et
al, 1981; Veigl et al, 1984; Rasmussen and Means, 1987, 1989; Lu
and Means, 1993). Early studies from our laboratory and others
detected increased CaM in malignant cells (Hait and DeRosa,
1988; Rasmussen and Means, 1989; Lu and Means, 1993), and
demonstrated that drugs that bind directly to CaM and inhibit its
function were both antiproliferative and cytotoxic to breast cancer
cells (Hait and Lee, 1985; Ford et al, 1989). Studies by Means and
colleagues demonstrated that overexpression of a CaM minigene
increased proliferation, and we and others found CaM antisense to
be antiproliferative and cytotoxic (Rasmussen and Means, 1989;
Prostko et al, 1997).
CaM kinase III may also provide important new insights into the
molecular coordination required for cell proliferation because this
enzyme transiently inhibits protein synthesis through the phosphoryl-
ation of eEF-2 (Ryazanov and Spirin, 1993). The activation of CaM
kinase III and subsequent inhibition of protein synthesis may help to
explain a variety of experimental observations; transient inhibition of
protein synthesis is an early event in mitogenesis (Fan and Penman,
1970; Celis et al, 1990). Furthermore, inhibitors of protein synthesis
such as cycloheximide and anisomycin mimic many effects of
growth factors, including the stimulation of cells into S-phase
(Muller et al, 1984; Greenberg et al, 1986). The requirement for this
effect is still unknown, but may represent a cellular mechanism for
the degradation of short-lived cell cycle repressors (Ryazanov and
Spirin, 1993). Thus, the rapid activation of CaM kinase III activity by
mitogens may help explain the mechanism by which the cell may
release itself from a cell cycle checkpoint.
To determine the stage of the cell cycle in which CaM kinase III
activity was expressed, non-synchronized populations of MCF-7
cells were sorted and analysed. Figure 4 demonstrates that the
activity of CaM kinase III per cell increased two- to threefold in
non-synchronized S-phase cells. The data are similar to those of
Carlberg et al (1991), who also found that CaM kinase III was
increased during the S-phase of the cell cycle in Ehrlich ascites
cells. Okmura-Noji and co-workers (1990) found that glial matura-
tion factor increased the activity of CaM kinase III in glioblasts
and glioblastoma cells as they entered the S-phase, and that this
increase was blocked by a CaM antagonist.
In summary, these studies demonstrate that CaM kinase III
activity is markedly elevated in human breast cancer. Furthermore,
the activity of the enzyme is regulated by growth factors, and
drugs that inhibit CaM kinase III activity block cell proliferation.
These data suggest that aberrant CaM-dependent cell signalling
pathways exist in human breast cancer and that CaM kinase III
may represent a new target for novel anti-cancer therapies.
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